Research news

A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai has begun at UCLH with participants now being screened.

A major new consortium led by UCLH and UCL has been awarded £6.8 million by the National Institute of Health Research to conduct the largest clinical study of long COVID over the next two years.

A record 119 patients have been recruited to the UCLH-led, charitably funded, IPI-GLIO immunotherapy clinical trial for NHS patients recently diagnosed with glioblastoma brain cancer.

UCLH, UCL and spinout company Odin Vision have used artificial intelligence (AI) to help detect early signs of oesophageal cancer in a global first.

Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains, according to laboratory findings from UCLH and the Francis Crick Institute.